Advertisement: EY
Advertisement: Lynch Wood Park
Advertisement: Bradfield Centre mid
Advertisement: KISS
RealVNC mid banner careers
RealVNC mid-banner general
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement: CPL mid banner
Advertisement: TTP
Advertisement Cambridge China Centre
Barr Ellison Solicitors – commercial property
Advertisement: Stansted Travel Show
Advertisement: Wild Knight Vodka
Advertisement: Bridge Fibre mid
Advertisement: Mobas mid banner
10 September, 2018 - 09:25 By Tony Quested

Cambridge-California alliance tackles drug abuse

consort medical, respiratory, inhalers, astrazeneca, cambridge

Cambridge UK business Consort Medical and California company Opiant Pharmaceuticals are fast-tracking a solution to treat drug overdoses. Opioid overdose is the leading cause of death in the US for adults under the age of 50.

The transatlantic partners are collaborating to develop an effective delivery device for Opiant’s OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of drug overdose.

They want to produce a ready-to-use nasal-delivered version of nalmefene.  Both of Consort’s wholly owned subsidiaries, Aesica in Hemel Hempstead and Bespak in King’s Lynn, will work with Opiant to produce a clinically pre-filled Unidose Xtra device with nalmefene. 

Aesica will supply Opiant with clinical samples and registration batches for the purposes of performing clinical studies and obtaining regulatory approvals. 

Also, on approval by the U.S. Food and Drug Administration (FDA), Aesica and Bespak will manufacture and supply the Unidose Xtra device for commercial purposes. The programme will be added to Consort’s development pipeline and be referred to as NAS040.

Jonathan Glenn (pictured), Consort Medical’s chief executive officer, said: “This agreement with Opiant highlights our expertise in the nasal delivery of drugs and the value of our unique offering of providing both drug manufacturing and delivery capabilities alongside one another.”

Newsletter Subscription

Stay informed of the latest news and features